QQQ
+ 0.00
383.13
+ 0%
BTC/USD
-843.99
48552.34
-1.71%
DIA
+ 0.00
346.24
+ 0%
SPY
-0.18
453.60
-0.04%
TLT
+ 0.00
154.35
+ 0%
GLD
+ 0.00
166.63
+ 0%

Why Moderna Shares Are Rebounding From Friday's Losses

October 18, 2021 12:27 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Why Moderna Shares Are Rebounding From Friday's Losses

Moderna, Inc. (NASDAQ:MRNA) shares have followed a downtrend ever since completing a double top formation in late September. After bottoming in early October, the stock reversed course and moved higher in anticipation of authorization for its COVID-19 booster shot.

U.S. Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee recommended late Thursday that the FDA grant an emergency use authorization for a booster dose of its COVID-19 vaccine for a select high-risk population.

In a buy-the-rumor, sell-the-news move, the stock trended lower Friday after advancing 13% from the Oct. 7 low of $293.58. It settled Friday's session down 2.3% at $324.21.

Moderna is recouping the losses, trading up 4.11% at $337.52 midday Monday. 

The chief catalyst is an upgrade of its shares by CFRA from Hold to Buy with a $385 price target.

On Friday, Piper Sandler analyst Edward Tenthoff upgraded Moderna shares from Neutral to Overweight while maintaining the price target at $445. The analyst premised his upgrade on a recent stock retreat that he said has rendered the valuation attractive.

Separately, a Financial Times report, citing data from Airfinity, said Moderna, along with Pfizer, Inc. (NYSE:PFE)-BioNTech (NASDAQ:BNTX), will generate $93.2 billion in combined COVID-19 vaccine sales in 2022, double the amount generated in 2021.

The two companies will likely control about 75% of the non-Chinese COVID19 vaccine market in 2022, the report said.

Related Link: The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst

Pfizer's COVID-19 Franchise Could Push Revenue Past $100B In 2022: Analyst

Pfizer, Inc. read more
Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst

Merck's Oral COVID-19 Treatment Could Be Game-Changer: BofA Analyst

Merck & Co., Inc. read more
Pfizer, BioNTech Analysts On FDA Panel's COVID-19 Booster Dose Decision

Pfizer, BioNTech Analysts On FDA Panel's COVID-19 Booster Dose Decision

Pfizer, Inc. read more
Moderna Analysts Debate Need For Biopharma's COVID-19 Booster Shot

Moderna Analysts Debate Need For Biopharma's COVID-19 Booster Shot

Moderna, Inc. read more